Martin Reck

53.0k total citations · 19 hit papers
339 papers, 20.3k citations indexed

About

Martin Reck is a scholar working on Pulmonary and Respiratory Medicine, Oncology and Cancer Research. According to data from OpenAlex, Martin Reck has authored 339 papers receiving a total of 20.3k indexed citations (citations by other indexed papers that have themselves been cited), including 280 papers in Pulmonary and Respiratory Medicine, 252 papers in Oncology and 55 papers in Cancer Research. Recurrent topics in Martin Reck's work include Lung Cancer Treatments and Mutations (257 papers), Lung Cancer Research Studies (106 papers) and Cancer Immunotherapy and Biomarkers (104 papers). Martin Reck is often cited by papers focused on Lung Cancer Treatments and Mutations (257 papers), Lung Cancer Research Studies (106 papers) and Cancer Immunotherapy and Biomarkers (104 papers). Martin Reck collaborates with scholars based in Germany, United States and Spain. Martin Reck's co-authors include Fabrice Barlési, Solange Peters, Keith M. Kerr, Sanjay Popat, Silvia Novello, Tony Mok, Mark A. Socinski, Federico Cappuzzo, Delvys Rodríguez‐Abreu and Robert M. Jotte and has published in prestigious journals such as New England Journal of Medicine, The Lancet and Nature Medicine.

In The Last Decade

Martin Reck

320 papers receiving 20.0k citations

Hit Papers

5 papers align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Atezolizumab for First-Line Treatment of Metastatic Nonsquamous NSCLC

2018 2.6k citations Mark A. Socinski, Fabrice Barlési et al. profile →
Metastatic non-small-cell lung cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up

2016 1.9k citations Silvia Novello, Fabrice Barlési et al. Annals of Oncology profile →
Metastatic non-small cell lung cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up

2018 1.6k citations David Planchard, Sanjay Popat et al. Annals of Oncology profile →
Gefitinib versus docetaxel in previously treated non-small-cell lung cancer (INTEREST): a randomised phase III trial

2008 1.0k citations Mark A. Socinski, Martin Reck et al. profile →
Ipilimumab in Combination With Paclitaxel and Carboplatin As First-Line Treatment in Stage IIIB/IV Non–Small-Cell Lung Cancer: Results From a Randomized, Double-Blind, Multicenter Phase II Study

2012 816 citations Fabrice Barlési, Martin Reck et al. Journal of Clinical Oncology profile →
Docetaxel plus nintedanib versus docetaxel plus placebo in patients with previously treated non-small-cell lung cancer (LUME-Lung 1): a phase 3, double-blind, randomised controlled trial

2014 694 citations Martin Reck, С. В. Орлов et al. profile →
Atezolizumab plus bevacizumab and chemotherapy in non-small-cell lung cancer (IMpower150): key subgroup analyses of patients with EGFR mutations or baseline liver metastases in a randomised, open-label phase 3 trial

2019 688 citations Martin Reck, Makoto Nishio et al. profile →
Metastatic non-small-cell lung cancer (NSCLC): ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up

2014 544 citations Martin Reck, Sanjay Popat et al. Annals of Oncology profile →
Ipilimumab in combination with paclitaxel and carboplatin as first-line therapy in extensive-disease-small-cell lung cancer: results from a randomized, double-blind, multicenter phase 2 trial

2012 500 citations Martin Reck, Fabrice Barlési et al. Annals of Oncology profile →
Oncogene-addicted metastatic non-small-cell lung cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up

2023 370 citations Lizza Hendriks, David Planchard et al. Annals of Oncology profile →
Molecular Testing Guideline for the Selection of Patients With Lung Cancer for Treatment With Targeted Tyrosine Kinase Inhibitors: American Society of Clinical Oncology Endorsement of the College of American Pathologists/International Association for the Study of Lung Cancer/Association for Molecular Pathology Clinical Practice Guideline Update

2018 342 citations Natasha B. Leighl, Suresh S. Ramalingam et al. Journal of Clinical Oncology profile →
IMpower150 Final Overall Survival Analyses for Atezolizumab Plus Bevacizumab and Chemotherapy in First-Line Metastatic Nonsquamous NSCLC

2021 316 citations Mark A. Socinski, Makoto Nishio et al. Journal of Thoracic Oncology profile →
Dual EGFR-VEGF Pathway Inhibition: A Promising Strategy for Patients With EGFR-Mutant NSCLC

2020 228 citations Martin Reck, Kazuhiko Nakagawa et al. Journal of Thoracic Oncology profile →
Targeting KRAS in non-small-cell lung cancer: recent progress and new approaches

2021 196 citations Martin Reck, David P. Carbone et al. Annals of Oncology profile →
Pembrolizumab Plus Concurrent Chemoradiation Therapy in Patients With Unresectable, Locally Advanced, Stage III Non–Small Cell Lung Cancer

2021 162 citations Salma K. Jabbour, Ki Hyeong Lee et al. profile →
Non-small-cell lung cancer

2024 127 citations Lizza Hendriks, Jordi Remón et al. profile →
Overall survival with adjuvant atezolizumab after chemotherapy in resected stage II-IIIA non-small-cell lung cancer (IMpower010): a randomised, multicentre, open-label, phase III trial

2023 126 citations Enriqueta Felip, Nasser K. Altorki et al. Annals of Oncology profile →
Immune-checkpoint inhibition for resectable non-small-cell lung cancer — opportunities and challenges

2023 105 citations Jordi Remón, Lizza Hendriks et al. Nature Reviews Clinical Oncology profile →
Association of Immune-Related Adverse Events With Efficacy of Atezolizumab in Patients With Non–Small Cell Lung Cancer

2023 102 citations Mark A. Socinski, Makoto Nishio et al. profile →

Peers

Countries citing papers authored by Martin Reck

Since Specialization

Citations

This map shows the geographic impact of Martin Reck's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Martin Reck with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Martin Reck more than expected).

Fields of papers citing papers by Martin Reck

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Martin Reck. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Martin Reck. The network helps show where Martin Reck may publish in the future.

Co-authorship network of co-authors of Martin Reck

This figure shows the co-authorship network connecting the top 25 collaborators of Martin Reck. A scholar is included among the top collaborators of Martin Reck based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Martin Reck. Martin Reck is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Distinct genomic profile of pediatric lung carcinoma: High frequency of ALK fusions and TP53 mutations compared to adults 2025 ·Lung Cancer ·Michael Abele, (unknown), (unknown), Ulrike Faust, Sorin Armeanu–Ebinger, Jakob Admard, (unknown), Irina Bonzheim, Nicolas Waespe, (unknown), Andreas De Block, Martin Reck, Ewa Bień, Małgorzata Krawczyk, Dominik T. Schneider, Stephan Ossowski, Ines B. Brecht, Christopher Schroeder	1
2	Unresectable stage III non-small-cell lung cancer: state of the art and challenges 2025 ·Nature Reviews Clinical Oncology ·Jordi Remón, Antonin Lévy, (unknown), (unknown), (unknown), Lizza Hendriks, Corinne Faivre‐Finn, Natasha B. Leighl, Martin Reck, M. Pérol	0
3	PP01.72 Randomized Phase-3 Study: Tarlatamab, a DLL3-targeting Bispecific T-cell engager (BiTE), Compared to Standard-of-Care in Relapsed Small Cell Lung Cancer (DeLLphi-304) 2024 ·Journal of Thoracic Oncology ·Luis Paz-Ares Rodríguez, Enriqueta Felip, Myung‐Ju Ahn, Fiona Blackhall, Hossein Borghaei, Byoung Chul Cho, Melissa L. Johnson, Suresh S. Ramalingam, Martin Reck, Tony T. Jiang, Chia‐Hsin Ju, Mukul Minocha, Sujoy Mukherjee, Gaurav Suri, Gonzálo Recondo, Pablo Martínez	1
4	MDT-BRIDGE: Neoadjuvant Durvalumab Plus Chemotherapy Followed by Either Surgery and Adjuvant Durvalumab or Chemoradiotherapy and Consolidation Durvalumab in Resectable or Borderline-resectable Stage IIB–IIIB NSCLC 2024 ·Clinical Lung Cancer ·Martin Reck, Ernest Nadal, Nicolas Girard, Andrea Riccardo Filippi, Linda W. Martin, Carl M. Gay, Cordula Petersen, Davina Gale, (unknown), Nefeli Georgoulia, (unknown), Jonathan Spicer	12
5	Four-year outcomes and circulating tumor DNA (ctDNA) analysis of pembrolizumab (pembro) plus concurrent chemoradiation therapy (cCRT) in unresectable, locally advanced, stage III non–small-cell lung cancer (NSCLC): From KEYNOTE-799. 2024 ·Journal of Clinical Oncology ·Martin Reck, Ki Hyeong Lee, Nikolaj Frost, В. В. Бредер, Dariusz M. Kowalski, E. Levchenko, Noemı́ Reguart, Alex Martínez‐Martí, Baerin Houghton, Jean-Baptiste Paoli, (unknown), Liu Hong, (unknown), Elisha J. Dettman, Julie Kobie, Salma K. Jabbour	3
6	Five-year outcomes with first-line (1L) nivolumab + ipilimumab + chemotherapy (N + I + C) vs C in patients (pts) with metastatic NSCLC (mNSCLC) in CheckMate 9LA. 2024 ·Journal of Clinical Oncology ·Martin Reck, Tudor–Eliade Ciuleanu, Michael Schenker, Stéphanie Bordenave-Juchereau, Manuel Cobo, Óscar Juan, Niels Reinmuth, Eduardo Richardet, Enriqueta Felip, J. Menezes, Ying Cheng, Hideaki Mizutani, David P. Carbone, Shun Lü, Thomas John, (unknown), Javed Mahmood, Nan Hu, Laura J. Eccles, Luis Paz‐Ares	6
7	Efficacy of nivolumab/ipilimumab as first-line treatment of pleural mesothelioma in the German real-world setting. 2024 ·Journal of Clinical Oncology ·Rajiv Shah, Martin Reck, Christian Grohé, Daniel C. Christoph, (unknown), Felix Carl Saalfeld, Nikolaj Frost, Hans‐Georg Kopp, Martin Faehling, Frank Griesinger, (unknown), Petra Hoffknecht, Jonas Kuon, (unknown), (unknown), (unknown), Michael Thomas	1
8	Abstract CT005: AEGEAN: A phase 3 trial of neoadjuvant durvalumab + chemotherapy followed by adjuvant durvalumab in patients with resectable NSCLC 2023 ·Cancer Research ·John V. Heymach, David H. Harpole, Tetsuya Mitsudomi, Janis M. Taube, Gabriella Gálffy, Maximilian J. Hochmair, Thomas Winder, Р. А. Зуков, Gabriel Garbaos, Shugeng Gao, Hiroaki Kuroda, Jian You, Kang‐Yun Lee, Lorenzo Antonuzzo, Mike Aperghis, Gary J. Doherty, Helen Mann, Tamer M. Fouad, Martin Reck	55
9	Overall survival with adjuvant atezolizumab after chemotherapy in resected stage II-IIIA non-small-cell lung cancer (IMpower010): a randomised, multicentre, open-label, phase III trial breakdown → 2023 ·Annals of Oncology ·Enriqueta Felip, Nasser K. Altorki, Caicun Zhou, Eric Vallières, Alex Martínez‐Martí, Achim Rittmeyer, Antonio Chella, Martin Reck, (unknown), Meijuan Huang, (unknown), Virginia McNally, Minu K. Srivastava, Elizabeth Bennett, (unknown), (unknown)	126
10	LBA63 SAPPHIRE: Phase III study of sitravatinib plus nivolumab versus docetaxel in patients with previously treated advanced non-squamous non-small cell lung cancer (NSCLC) 2023 ·Annals of Oncology ·Hossein Borghaei, Melissa L. Johnson, Edward B. Garon, Kai He, David Planchard, Martin Reck, Sanjay Popat, Roy S. Herbst, Ticiana Leal, Daphne W. Dumoulin, Filippo de Marinis, Charles H. Reynolds, Willemijn S.M.E. Theelen, Ivor Percent, (unknown), (unknown), Ronald Shazer, Xin Yan, (unknown), (unknown)	4
11	Tumor Dynamic Model-Based Decision Support for Phase Ib/II Combination Studies: A Retrospective Assessment Based on Resampling of the Phase III Study IMpower150 2023 ·Clinical Cancer Research ·René Bruno, Mathilde Marchand, Kenta Yoshida, Phyllis Chan, Haocheng Li, Wei Zou, François Mercier, Pascal Chanu, Benjamin Wu, (unknown), Chunze Li, Jin Y. Jin, Michael L. Maitland, Martin Reck, Mark A. Socinski	13
12	RELAY Subgroup Analyses by EGFR Ex19del and Ex21L858R Mutations for Ramucirumab Plus Erlotinib in Metastatic Non–Small Cell Lung Cancer 2021 ·Clinical Cancer Research ·Kazuhiko Nakagawa, Ernest Nadal, Edward B. Garon, Makoto Nishio, Takashi Seto, Nobuyuki Yamamoto, Keunchil Park, Jin‐Yuan Shih, Luis Paz‐Ares, Bente Frimodt‐Moller, Annamaria H. Zimmermann, Sameera R. Wijayawardana, Carla Visseren‐Grul, Martin Reck, (unknown)	29
13	MA07.02 Evaluating Circulating Tumor DNA to Predict Overall Survival Risk in Non-Squamous Non-Small Cell Lung Cancer in IMpower150 2021 ·Journal of Thoracic Oncology ·Zoe J. Assaf, Alexander D. Fine, Wei Zou, Mark A. Socinski, Andrew N. Young, (unknown), Mark Kennedy, Eliana Polisecki, Makoto Nishio, Geoffrey R. Oxnard, (unknown), Anja Rode, Martin Reck, Nirav Patil, (unknown), K.‐D. Schulz	2
14	Nintedanib Plus Pemetrexed/Cisplatin in Patients With Malignant Pleural Mesothelioma: Phase II Results From the Randomized, Placebo-Controlled LUME-Meso Trial 2017 ·Journal of Clinical Oncology ·Federica Grosso, Nicola Steele, Silvia Novello, Anna K. Nowak, Sanjay Popat, Laurent Greillier, Thomas John, Natasha B. Leighl, Martin Reck, Paul Taylor, David Planchard, Jens Benn Sørensen, Mark A. Socinski, Ute von Wangenheim, (unknown), José Barrueco, Nassim Morsli, Giorgio V. Scagliotti	77
15	Epigenetic modifications of the immune-checkpoint genes CTLA4 and PDCD1 in non-small cell lung cancer results in increased expression 2017 ·Clinical Epigenetics ·Sebastian Marwitz, (unknown), Sven Perner, Martin Reck, Ole Ammerpohl, Torsten Goldmann	54
16	Randomized, Placebo-Controlled, Phase II Study of Veliparib in Combination with Carboplatin and Paclitaxel for Advanced/Metastatic Non–Small Cell Lung Cancer 2016 ·Clinical Cancer Research ·Suresh S. Ramalingam, Normand Blais, Julien Mazières, Martin Reck, C. Michael Jones, Erzsébet Juhász, László Urbán, С. В. Орлов, Fabrice Barlési, Ebenezer A. Kio, (unknown), Qin Qin, Jiang Qian, Caroline Nickner, (unknown), Hao Xiong, Peter Ansell, Mark D. McKee, Vincent L. Giranda, В. А. Горбунова	65
17	Bevacizumab Prevents Brain Metastases Formation in Lung Adenocarcinoma 2016 ·Molecular Cancer Therapeutics ·Aysegül Ilhan‐Mutlu, Matthias Osswald, Yunxiang Liao, Miriam Gömmel, Martin Reck, David Miles, Paola Mariani, Luca Gianni, Beatrix Lutiger, (unknown), Stefanie Srock, Pablo Ernesto Pérez, Frits Thorsen, Louisa von Baumgarten, Matthias Preusser, Wolfgang Wick, Frank Winkler	86
18	A randomized Phase 2 study of pemetrexed in combination with cisplatin or carboplatin as adjuvant chemotherapy in patients with completely resected stage IB or II Non-Small-Cell Lung Cancer 2015 ·Lung Cancer ·Gerald Schmid‐Bindert, Walburga Engel-Riedel, Martin Reck, Wolfgang Schuette, (unknown), Jürgen R. Fischer, Julien Mazières, C. Chouaïd, M. Wolf, Núria Viñolas, Victoria Soldatenkova, Veronique Ripoche, Tuan S. Nguyen, Carla Visseren‐Grul	9
19	Safety and Immunogenicity of MAGE-A3 Cancer Immunotherapeutic with or without Adjuvant Chemotherapy in Patients with Resected Stage IB to III MAGE-A3-Positive Non-Small-Cell Lung Cancer 2015 ·Journal of Thoracic Oncology ·Jean-Louis Pujol, Johan Vansteenkiste, Tommaso Martino De Pas, Djordje Atanackovic, Martin Reck, Michiel Thomeer, Jean-Yves Douillard, Gianpiero Fasola, Vanessa Potter, Paul Taylor, Lionel Bosquée, Robert Scheubel, (unknown), Muriel Debois, (unknown), Jamila Louahed, Vincent Brichard, Frédéric Lehmann	51
20	Phase II Clinical Trial of Amatuximab, a Chimeric Antimesothelin Antibody with Pemetrexed and Cisplatin in Advanced Unresectable Pleural Mesothelioma 2014 ·Clinical Cancer Research ·Raffit Hassan, Hedy L. Kindler, Thierry Jahan, Lyudmila Bazhenova, Martin Reck, Anish Thomas, Ira Pastan, (unknown), Daniel J. O’Shannessy, (unknown), Julia D. Maltzman, Bruce A. Wallin	139

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact